Cargando…

IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas

Glioma is the most common malignant tumor in the central nervous system (CNS). Lower-grade gliomas (LGG) refer to Grade II and III gliomas. In LGG patients, seizure often appears as an initial symptom and play an important role in clinical performance and quality of life of the patients. To date, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duan, Wen-chao, Wang, Li, Li, Ke, Wang, Wei-wei, Zhan, Yun-bo, Zhang, Feng-jiang, Yu, Bin, Bai, Ya-hui, Wang, Yan-min, Ji, Yu-chen, Zhou, Jin-qiao, Liu, Xian-zhi, Zhang, Zhen-yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320119/ https://www.ncbi.nlm.nih.gov/pubmed/30558073 http://dx.doi.org/10.1097/MD.0000000000013675

Ejemplares similares

Seizures in patients with IDH-mutated lower grade gliomas
por: Carstam, Louise, et al.
Publicado: (2022)

TERTmonitor—qPCR Detection of TERTp Mutations in Glioma
por: Brás, João Paulo, et al.
Publicado: (2023)

Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [(18)F]FET PET radiomics
por: Li, Zhicong, et al.
Publicado: (2021)

Pharmacoresistant seizures and IDH mutation in low-grade gliomas
por: Correia, Carlos Eduardo, et al.
Publicado: (2021)

IDH mutation-specific radiomic signature in lower-grade gliomas
por: Liu, Xing, et al.
Publicado: (2019)

Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss
por: Li, Xia, et al.
Publicado: (2017)

The Significance of IDH1 Mutations in Tumor-Associated Seizure in 60 Chinese Patients with Low-Grade Gliomas
por: Liang, Ruofei, et al.
Publicado: (2013)

Hypermethylation of LATS2 Promoter and Its Prognostic Value in IDH-Mutated Low-Grade Gliomas
por: Gu, Yuan, et al.
Publicado: (2020)

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
por: Wang, Hao-Yuan, et al.
Publicado: (2016)

Vessel Size Imaging is Associated with IDH Mutation and Patient Survival in Diffuse Lower-Grade Glioma
por: Kang, Houyi, et al.
Publicado: (2020)

IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas
por: Zhang, Lei, et al.
Publicado: (2018)

The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET
por: Liu, Feng-Min, et al.
Publicado: (2021)

Construction of ceRNA networks with different types of IDH1 mutation status in low-grade glioma patients
por: Wang, Wen-Jie, et al.
Publicado: (2022)

Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations
por: Persico, Pasquale, et al.
Publicado: (2022)

Clinicopathological analysis of HOXD4 expression in diffuse gliomas and its correlation with IDH mutations and 1p/19q co-deletion
por: Zhao, Xin-Wei, et al.
Publicado: (2017)

BIMG-15. LACTATE AND GLUTATHIONE LEVELS DETECTED WITH PROTON MR SPECTROSCOPY ARE ASSOCIATED WITH POOR SURVIVAL IN IDH WILD TYPE TERTP MUTANT DIFFUSE GLIOMAS
por: Sacli-Bilmez, Banu, et al.
Publicado: (2021)

MPC-01 PROGNOSTIC ROLE OF TERT PROMOTER IMPROVES THE STRATIFICATION OF IDH-MUTATED LOWER GRADE GLIOMA
por: Arita, Hideyuki, et al.
Publicado: (2019)

Predicting prognosis and IDH mutation status for patients with lower-grade gliomas using whole slide images
por: Jiang, Shuai, et al.
Publicado: (2021)

Quantitative analysis of neurite orientation dispersion and density imaging in grading gliomas and detecting IDH-1 gene mutation status
por: Zhao, Jing, et al.
Publicado: (2018)

TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas
por: Zhang, Zhen-Yu, et al.
Publicado: (2015)

Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival
por: Yao, Yu, et al.
Publicado: (2013)

Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas
por: Chang, Yu-Zhou, et al.
Publicado: (2020)

Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma
por: Chai, Rui-Chao, et al.
Publicado: (2019)

Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1
por: Alghamri, Mahmoud S, et al.
Publicado: (2020)

IDH1 mutation detection by droplet digital PCR in glioma
por: Wang, Jing, et al.
Publicado: (2015)

Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma
por: Lin, Wanzun, et al.
Publicado: (2021)

Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period
por: Svenjeby, Caroline, et al.
Publicado: (2022)

Markedly prolonged disease course, with breakthrough seizures, in a glioma with an isolated IDH1 mutation
por: Drumm, Michael, et al.
Publicado: (2022)

IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma
por: Chen, Xueqin, et al.
Publicado: (2023)

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins
por: Kaminska, Bozena, et al.
Publicado: (2019)

Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas
por: Bendahou, Mohammed Amine, et al.
Publicado: (2020)

Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas
por: Wang, Lei-Ming, et al.
Publicado: (2019)

TERTp mutations and p53 expression in head and neck cutaneous basal cell carcinomas with different aggressive features
por: Castanheira, António, et al.
Publicado: (2021)

Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression
por: Givechian, Kevin B, et al.
Publicado: (2020)

RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma
por: Wang, Haiwei, et al.
Publicado: (2021)

Association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas
por: Liouta, Evangelia, et al.
Publicado: (2022)

Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3
por: Eichkorn, Tanja, et al.
Publicado: (2023)

DZIP3 is a key factor to stratify IDH1 wild-type lower-grade gliomas
por: Liang, Tingyu, et al.
Publicado: (2020)

MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status
por: Li, Guanzhang, et al.
Publicado: (2018)

Qualitative and Quantitative MRI Analysis in IDH1 Genotype Prediction of Lower-Grade Gliomas: A Machine Learning Approach
por: Cao, Mengqiu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_39p6bjto7r10glv3lfv00qr5lo